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The impact of suc-
cessful CTO recan-
alization on long-
term survival
remains unsettled.
Since the leading
cause for referral to
surgery instead of
PCI remains the
presence of CTO,
would it not be
reasonable to per-
form a randomized
trial of revascular-
ization with PCI
or coronary artery
bypass grafting
(CABG) compared
to optimal medical
therapy in patients
with manageable
stable ischemic
heart disease?EDITOR’S PAGE
Chronic Total Occlusion:
A Job for the “Heart Team”
I am often asked to speak about the development of percutaneous coronary interventions
(PCIs) and where they are projected to go in the future. When the subject turns to the fron-
tiers in coronary interventions, chronic total occlusion (CTO) always takes center stage. In this
issue of JACC: Cardiovascular Interventions, there are 3 articles and 1 editorial dealing with
issues related to CTO (1–4). One is a group effort at proposing an algorithm for approaching
CTO with the general concept of developing concentrated expertise in an organized approach
to CTOs; another is a specialized technique for an antegrade approach to CTO intervention;
and a third is reporting the survival benefit of successful CTO interventions compared to those
that are unsuccessful. The editorial makes the case for attempting more CTOs and reflects on
many observational studies that suggest improved survival with successful intervention on
CTOs compared with unsuccessful intervention. We have recently published other papers
aimed at improving our readership’s prowess in dealing with CTOs. Several CTO clubs have
sprung up in the United States, Japan, Europe, and other places because of the growing inter-
est in this subset of coronary interventions. With so much interest, one wonders why such a
small percentage of CTOs are undergoing attempted PCI. According to the latest guideline of
the American College of Cardiology/American Heart Association/Society for Cardiovascular
Angiography and Interventions, only 8% to 15% of patients with CTO undergo attempted
PCI (5). The reasons usually proposed for this are the technical difficulty and modest success
rate of CTO interventions, and the uncertainty of the clinical benefit.
As I read the editorial by Moses (4) (which is clearly from the perspective of a strong
advocate for CTO intervention) and the article by Jones et al. (3), with dramatic survival
benefit of successfully opened CTOs compared to those with failed attempts, I began to
wonder if CTO intervention should continue to be called the “unconquered frontier” or if in
fact its value has been well demonstrated. If this is true, why is the latest guideline more
reserved? The up-to-date guideline states, “studies suggest that patients who undergo
successful, rather than failed, recanalization of CTOs fair better in terms of symptom status
and need for CABG, as well as LV function. However, the impact of successful CTO
recanalization on long-term survival remains unsettled” (5). At this point in my dilemma, I
flipped back to the editorial by Moses (4), which cites a number of observational studies in
patients with successful CTO interventions. I was interested to find that the earliest large
series came from our own institution, Emory University Hospital (6). All of the CTOs we
treated between 1980 and 1988 with plain balloon angioplasty were reviewed. Although
comparing trials is fraught with error, I was surprised to rediscover that the success rate in
those dark ages was 66% compared to the 69.6% success rate in the study by Jones et al. (3),
which occurred between 2003 and 2010. The follow-up duration was similar in both trials and
both showed a similar odds ratio for mortality favoring the successfully treated group; 1980 to
1988 study, odds ratio 0.21 (95% confidence interval: 0.05 to 0.83) and 2003 to 2010 cohort,
odds ratio 0.28 (95% confidence interval: 0.15 to 0.52). Have we missed the clear-cut benefit
of opening CTOs for the past almost 30 years, or does the lack of embrace of a survival
benefit reflect something else? There are several suggested mechanisms by which
revascularizing totally occluded arteries could contribute to a survival benefit, including
decreased ischemia and arrhythmogenicity and improved left ventricular function. The survival
benefit, however, seems to far exceed the survival benefit for patients with stable ischemic heart
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459disease undergoing PCI overall. Another explanation
might be selection bias whereby patients with failed CTO
attempts in fact are sicker with more comorbidity.
Another, and more disturbing, possibility is that the failed
attempts at opening CTOs actually result in harm. One
would expect this effect to be primarily early and a lack of
high-hospital mortality in these trials would argue against
that occurring. If the mechanistic explanation for
improved survival with CTO revascularization holds true,
then should we not take advantage of all means to
provide revascularization for these patients? In the Emory
University trial, many of the patients who were
unsuccessfully recanalized with a PCI underwent
subsequent bypass surgery. If we believe that
recanalization of total occlusions provides such a potent
survival benefit, 5-year mortality 4.5% for successful PCI
versus 17.2% for failure in the Jones et al. (3) observation,
then failure should not be allowed. If the mechanism of
survival is related to the revascularization of the artery
then, when PCI is not possible, surgery should be done.
If this thesis is correct, then perhaps the surgical
consideration should come up front with the convening of
the “heart team” to consider what approach would be best
for each individual patient with CTO. The
aforementioned guideline states, “consultation with a
cardiothoracic surgeon and use of the heart team
approach in cases of CTO in which a large territory is
subtended and/or multivessel CAD is present are
frequently done” (5). Well, I do not know how frequently
it is done, but with so much hanging in the balance,
should that be routinely done? The conclusion from the
editorial (4) differs from the guideline in suggesting that
PCI should, in addition to symptomatic patients, be a
reasonable approach for those with 10% ischemia, those
with multivessel disease, and those who need
improvement in left ventricular function. The authors of
the papers and the editorial all admit that the evidence
for these claims is lacking and is sorely needed. After 35
years we still do not know if revascularization of CTOs
results in improved survival. A randomized trial is
referenced which will study patients with stable angina
assigned to optimal medical therapy or PCI and followed
for 36 months (7). Since the leading cause for referral to
surgery instead of PCI remains the presence of CTO,would it not be reasonable to perform a randomized trial
of revascularization with PCI or coronary artery bypass
grafting (CABG) compared to optimal medical therapy in
patients with manageable stable ischemic heart disease?
Such a trial could involve the heart team from the outset,
as was used in the SYNTAX (Synergy Between
Percutaneous Coronary Intervention with TAXUS and
Cardiac Surgery) trial. Patients with a projected high
failure rate with PCI could be referred directly for
CABG, and patients with unsuccessful PCI could
subsequently undergo CABG. The improved technical
prowess reflected by the papers in this issue combined
with surgery in the remnant of patients in whom that is
not possible could go a long way to finally answering the
question—should CTOs be opened to prolonged survival?
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